Ling Yu Jietao Lin Hanhan Li Lingling Sun Shubo Wang Yaoxu Chen Hanrui Chen Lizhu Lin
10.3389/fphar.2023.997760
Front Pharmacol
2023 Jan 23;14:997760.
brca1 anlotinib cancer of unknown primary large genomic rearrangement olaparib
CC BY
https://pubmed.ncbi.nlm.nih.gov/36755949/
Case Reports
PMC9899799
36755949
Case Report: Clinical benefit from multi-target tyrosine kinase inhibitor and PARP inhibitor in a patient with cancer of unknown primary with BRCA1 large genomic rearrangement
2023